The serum activity of thioredoxin reductases 1 (TrxR1) is correlated with the poor prognosis in EGFR wild-type and ALK negative non-small cell lung cancer.
The serum activity of thioredoxin reductases 1 (TrxR1) is correlated with the poor prognosis in EGFR wild-type and ALK negative non-small cell lung cancer.
复制标题
硫氧还蛋白还原酶 1 (TrxR1) 的血清活性与 EGFR 野生型和 ALK 阴性非小细胞肺癌的不良预后相关
DOI：
10.18632/oncotarget.23252
复制
发表时间：
2017-12-29
期刊：
影响因子：
--
通讯作者：
Zhang Y
中科院分区：
文献类型：
--
作者：
Chen G;Chen Q;Zeng F;Zeng L;Yang H;Xiong Y;Zhou C;Liu L;Jiang W;Yang N;Zhang Y
背景硫氧还蛋白还原酶1（TrxR 1）是哺乳动物细胞中主要的抗氧化和氧化还原调节因子之一。研究表明，TrxR 1在许多恶性疾病中过度表达。然而，很少有研究评估TrxR 1在非小细胞肺癌（NSCLC）中的作用。方法收集2013年6月至2016年2月湖南省肿瘤医院收治的142例EGFR野生型和ALK阴性的晚期NSCLC患者，采用ELISA法检测其一线标准双药化疗前血清TrxR 1和CEA水平。根据血清TrxR 1水平收集和分析临床特征和生存数据。结果与临床病理指标无显著性差异。以12 U/mL为界值，血清TrxR 1活性较低的患者与血清TrxR 1活性较高的患者相比，具有较长的无进展生存期（PFS）和总生存期（OS）（PFS：5.3 m vs. 3.6 m p=0.044，OS：14.5 m vs. 11 m p<0.001）。在亚组中，血清TrxR 1活性较低的患者在腺癌（ADC）（17个月vs. 8个月，p=0.003）和鳞状细胞癌（SCC）（13个月vs. 11个月，p=0.035）中的OS较长。结合TrxR 1活性和血清CEA浓度，发现血清TrxR 1活性和血清CEA浓度较低的患者OS较长（20个月vs.7个月，p<0.001）。结论血清TrxR 1活性不受临床病理因素的影响。血清TrxR 1活性测定可能是EGFR野生型和ALK阴性晚期NSCLC患者的独立预后因素。血清TrxR 1活性和血清CEA浓度的组合需要从实验室到旁边进一步分析。
Background The thioredxin reductases 1 (TrxR1) is one of the major antioxidant and redox regulators in mammalian cells. Studies have shown that TrxR1 is over expressed in many malignancy diseases. However, few studies have evaluated the role of TrxR1 in non-small cell lung cancer (NSCLC). Methods Serum levels of TrxR1 and CEA in 142 patients with EGFR wild type and ALK negative advanced NSCLC was measured by ELISA assay before first line standard doublet chemotherapy from June 2013 to February 2016 in Hunan Cancer Hospital. Clinical characteristics and Survival data were collected and analyzed according to serum TrxR1 levels. Results No significant differences were founded from clinic pathological variables. With the cut-off value of 12U/mL, the lower serum TrxR1 activity patients had long progression-free survival (PFS) and overall survival (OS) compared with higher patients (PFS: 5.3m vs. 3.6m p=0.044, OS: 14.5m vs. 11m p<0.001). In subgroup, lower serum TrxR1 activity patients had long OS both in adenocarcinoma (ADC) (17m vs. 8m, p=0.003) and squamous cell carcinoma (SCC) (13m vs. 11m, p=0.035). While combining with TrxR1 activity and serum CEA concentrations, we founded that patients with lower serum TrxR1 activity and serum CEA concentrations had long OS compared with higher group patients (20m vs. 7m, p<0.001). Conclusions Serum TrxR1 activity was not affected by clinic pathological variables. Measurement of serum TrxR1 activity might be an independent prognostic factor for EGFR wild type and ALK negative advanced NSCLC patients. Combination of serum TrxR1 activity and serum CEA concentrations need to be further profiled from bench to beside.
登录
查看更多内容
影响因子：
2.8
作者：
Saccoccia F;Angelucci F;Boumis G;Carotti D;Desiato G;Miele AE;Bellelli A
通讯作者：
Bellelli A
影响因子：
4.7
作者：
LEE, KB;PARKER, RJ;REED, E
通讯作者：
REED, E
影响因子：
5.3
作者：
Thongprasert, S;Sanguanmitra, P;Clinch, J
通讯作者：
Clinch, J
影响因子：
3.7
作者：
Marullo R;Werner E;Degtyareva N;Moore B;Altavilla G;Ramalingam SS;Doetsch PW
通讯作者：
Doetsch PW
影响因子：
--
作者：
Lu J;Wang Y;Yan M;Feng P;Yuan L;Cai Y;Xia X;Liu M;Luo J;Li L
通讯作者：
Li L